.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,273,379

« Back to Dashboard

Claims for Patent: 8,273,379

Title:Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Inventor(s): Warrell, Jr.; Raymond P. (Westfield, NJ), Pandolfi; Pier Paolo (New York, NY), Gabrilove; Janice L. (New York, NY)
Assignee: Memorial Sloan-Kettering Cancer Center (New York, NY)
Application Number:12/974,076
Patent Claims: 1. A method for treating a patient having a diagnosis of acute promyelocytic leukemia (APL) comprising administering to the patient a therapeutically effective amount of arsenic trioxide, wherein the diagnosis of APL in the patient involves assay for a t(15;17) chromosomal translocation or assay for expression of PML/RAR-.alpha..

2. The method of claim 1 wherein the assay for a t(15;17) chromosomal translocation is conducted using cytogenetics or fluorescence in situ hybridization (FISH).

3. The method of claim 1 wherein the expression of PML/RAR-.alpha. is assayed by reverse transcriptase polymerase chain reaction (RT-PCR).

4. The method of claim 1 wherein the therapeutically effective amount of arsenic trioxide is based on the body weight of the patient.

5. The method of claim 1 wherein the therapeutically effective amount of arsenic trioxide is about 0.001 to about 10.0 mg/kg body weight of the patient per day.

6. The method of claim 1 wherein the therapeutically effective amount of arsenic trioxide is about 0.05 to about 5.0 mg/kg body weight of the patient per day.

7. The method of claim 1 wherein the therapeutically effective amount of arsenic trioxide is about 0.01 to about 1.0 mg/kg body weight of the patient per day.

8. The method of claim 1 wherein the therapeutically effective amount of arsenic trioxide is about 0.15 mg of arsenic trioxide per kg of body weight of the patient per day.

9. The method of claim 1 wherein the arsenic trioxide is administered intravenously.

10. The method of claim 1 wherein the APL is refractory to conventional methods of treatment.

11. The method of claim 10 wherein the arsenic trioxide is administered to the patient in combination with all-trans retinoic acid (ATRA).

12. The method of claim 1 wherein the arsenic trioxide is administered to the patient in combination with another therapeutic agent.

13. The method of claim 12 wherein the arsenic trioxide is administered to the patient in combination with a chemotherapeutic agent.

14. The method of claim 12 wherein the arsenic trioxide is administered to the patient in combination with radiation treatment.

15. A method for treating a patient having a diagnosis of acute promyelocytic leukemia (APL) comprising administering to the patient a therapeutically effective amount of arsenic trioxide based on the body weight of the patient, wherein the diagnosis of APL in the patient involves assay for a t(15;17) chromosomal translocation or assay for expression of PML/RAR-.alpha..

16. The method of claim 15 wherein the assay for a t(15;17) chromosomal translocation is conducted using cytogenetics or fluorescence in situ hybridization (FISH) and expression of PML/RAR-.alpha. is assayed by reverse transcriptase polymerase (RT-PCR).

17. The method of claim 15 wherein the therapeutically effective amount of arsenic trioxide is about 0.15 mg of arsenic trioxide per kg of body weight of the patient per day.

18. The method of claim 15 wherein the arsenic trioxide is administered intravenously.

19. The method of claim 15 wherein the APL is refractory to conventional methods of treatment and the arsenic trioxide is administered to the patient in combination with all-trans retinoic acid (ATRA).

20. The method of claim 15 wherein the arsenic trioxide is administered to the patient in combination with a chemotherapeutic agent or radiation treatment.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc